Fig. 5From: A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementiaMean ADAS-Cog12 score change from baseline at weeks 4, 12, 24, and 36 (observed value) on the ADAS-Cog12 by the MMSE subgroup. Error bars represent standard errors (SE). p values are obtained from the Wilcoxon rank sum testsBack to article page